Swiss Infrastructure Stock News

Sandoz Group (SWX:SDZ) just kicked off a major European rollout of its Wyost and Jubbonti denosumab biosimilars, opening fresh exposure to a multibillion dollar cancer bone disease and osteoporosis market. See our latest analysis for Sandoz Group. The denosumab rollout lands at a strong moment for Sandoz, with a 30 day share price return of 9.77% and a 90 day share price return of 22.49% helping drive a 1 year total shareholder return of 60.6%. This suggests momentum is building as investors...

Key Insights The considerable ownership by individual investors in SoftwareOne Holding indicates that they collectively...

Recently, Relation Therapeutics announced a multi-program collaboration with Novartis in immuno-dermatology, combining US$55 million of upfront, equity and R&D funding with up to US$1.70 billion in potential milestones and royalties, alongside Novartis’s latest US FDA approval for Itvisma and strong Phase III trial results in immune thrombocytopenia and breast cancer. Together, these developments spotlight how Novartis is pairing AI-enabled target discovery with late-stage pipeline execution...

Swiss Prime Site has acquired a modern, fully let 19,000 m² office property on Pfingstweidstrasse in Zurich West, occupied entirely by SIX Group Services AG and benefiting from strong transport links and sustainable design features. This deal completes the deployment of the CHF 300 million raised in February for growth initiatives, adding higher-yielding assets that are expected to lift NAV and FFO per share while supporting recurring rental income of nearly CHF 20 million annually. We...

There wouldn't be many who think Sulzer Ltd's ( VTX:SUN ) price-to-earnings (or "P/E") ratio of 17.5x is worth a...

If you are wondering whether ABB is still a smart consideration after its strong multi year run, or if you might be late to the party, this breakdown is for you. ABB's share price has climbed 2.2% over the last week, 4.6% over the last month, and 19.4% year to date, adding to gains of 16.7% over 1 year, 112.4% over 3 years, and 190.1% over 5 years. Behind those moves, ABB has remained in the spotlight for its push into electrification and automation solutions, as well as strategic portfolio...

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...

What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a...

It is doubtless a positive to see that the Bellevue Group AG ( VTX:BBN ) share price has gained some 37% in the last...

UBS Group (SWX:UBSG) is back in focus after a Reuters report suggested Switzerland might soften proposed capital rules that would have forced the bank to fully fund key foreign subsidiaries with over $20 billion. See our latest analysis for UBS Group. The latest talk of softer capital rules has arrived alongside firm momentum in UBS Group, with a roughly 9.5 percent 1 month share price return and a powerful 5 year total shareholder return above 200 percent. This suggests investors are...

In early December 2025, Swiss Re AG set net income targets of more than US$4.40 billion for 2025 and US$4.50 billion for 2026, alongside confirming plans for a conditional share buyback program and ongoing business portfolio reviews. Investors are scrutinizing how these profit goals, seen as below prior market hopes, and the planned but modest share repurchases balance against Swiss Re’s AI-led transformation and cost-efficiency ambitions. We’ll now examine how Swiss Re’s below-expectation...

If you are wondering whether Nestlé is quietly becoming good value again, or if it is still priced for safety rather than upside, you are not alone. Plenty of long term investors are asking the same question. The stock is up 4.9% year to date and 7.3% over the last year, but those gains sit against a 21.5% slide over 3 years and a 9.5% drop over 5 years, suggesting the market is still recalibrating its expectations. Recent months have seen Nestlé in the headlines for portfolio reshaping and...

Newron Pharmaceuticals has initiated its ENIGMA-TRS 2 global Phase III trial of evenamide as an add-on therapy for treatment-resistant schizophrenia, following US FDA and IRB approvals, with the first site at UCLA’s Semel Translational Research Center for Neuropsychiatry. The study’s focus on rigorously defined treatment-resistant patients and evenamide’s targeted sodium-channel mechanism highlights its potential differentiation from existing antipsychotic options. Next, we’ll explore how...

In early December 2025, Holcim completed acquisitions of Thames Materials in West London and a majority stake in A&S Recycling in Germany, and agreed to buy a demolition materials recycler in Northwest France, adding around 1.3 million tons of annual permitted processing capacity to its European network. By integrating these recycling businesses into its ECOCycle® circular construction platform, Holcim is materially expanding access to low‑carbon, recycled construction solutions across...

EPIC Suisse (SWX:EPIC) has just wrapped up a CHF 70 million follow on equity offering at about CHF 80 a share. This deal could subtly reset how investors think about its valuation. See our latest analysis for EPIC Suisse. Despite the modest discount to the CHF 80 offer price, the current CHF 81.8 share price and flat year to date share price return sit alongside a much stronger 1 year total shareholder return of 9.7 percent and robust 3 year total shareholder return of 53.9 percent. This...

As European markets show mixed returns with the STOXX Europe 600 Index inching higher on hopes of interest rate cuts, investors are keenly observing economic indicators such as inflation and GDP revisions. In this environment, identifying undervalued stocks can be a strategic move, as these equities may offer potential for growth when market conditions stabilize.

It's not a stretch to say that Emmi AG's ( VTX:EMMN ) price-to-earnings (or "P/E") ratio of 18.1x right now seems quite...

Dottikon ES Holding (VTX:DESN) has had a great run on the share market with its stock up by a significant 18% over the...

It is hard to get excited after looking at Clariant's (VTX:CLN) recent performance, when its stock has declined 12...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Vetropack Holding AG's ( VTX:VETN ) price-to-earnings (or "P/E") ratio of 28.5x might make it look like a sell right...

Basilea Pharmaceutica's (VTX:BSLN) stock is up by a considerable 17% over the past month. Given that the market rewards...

If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost...

Sika (SWX:SIKA) just pulled back the curtain on its Fast Forward program, a multi year push to digitize its value chain, streamline operations, and reshape its footprint, especially in China. See our latest analysis for Sika. The Fast Forward announcement lands after a tough stretch, with the share price down sharply on a year to date basis and the one year total shareholder return also deeply negative. This suggests sentiment has cooled even as management signals a profitability reset. If...